Information  X 
Enter a valid email address

Company Name matching 'ObsEva SA'

Date
Time Source
Company
Announcement
12 Jul 2019 6:00 am GNW     ObsEva SA ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
08 Jul 2019 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
01 Jul 2019 6:00 am GNW     ObsEva SA ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
21 Jun 2019 6:00 am GNW     ObsEva SA ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
19 Jun 2019 6:00 am GNW     ObsEva SA ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
04 Jun 2019 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
16 May 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
09 May 2019 6:15 am GNW     ObsEva SA ObsEva Reports First Quarter 2019 Financial Results
  6:00 am GNW     ObsEva SA ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
08 May 2019 9:30 pm GNW     ObsEva SA ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
03 May 2019 6:00 am GNW     ObsEva SA ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
01 May 2019 6:00 am GNW     ObsEva SA ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
29 Apr 2019 6:00 am GNW     ObsEva SA ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
01 Apr 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
29 Mar 2019 6:00 am GNW     ObsEva SA Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
13 Mar 2019 6:00 am GNW     ObsEva SA ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
05 Mar 2019 6:00 am GNW     ObsEva SA ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
27 Feb 2019 6:00 am GNW     ObsEva SA ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
22 Feb 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
23 Jan 2019 8:28 am GNW     ObsEva SA Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
02 Jan 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
21 Dec 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
07 Dec 2018 5:12 pm GNW     ObsEva SA ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
06 Dec 2018 6:00 am GNW     ObsEva SA ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
29 Nov 2018 6:30 am GNW     ObsEva SA ObsEva SA to Host R&D Investor Day December 7, 2018
28 Nov 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
08 Nov 2018 6:15 am GNW     ObsEva SA ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
07 Nov 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in November Investor Conferences
31 Oct 2018 6:30 am GNW     ObsEva SA ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018
09 Oct 2018 9:15 pm GNW     ObsEva SA ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
05 Oct 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
03 Oct 2018 6:00 am GNW     ObsEva SA ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
28 Sep 2018 6:00 am GNW     ObsEva SA Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
28 Aug 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in September Investor Conferences
10 Aug 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018
08 Aug 2018 6:00 am GNW     ObsEva SA ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update
31 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
25 Jul 2018 6:30 am GNW     ObsEva SA ObsEva Expands Executive Team Hiring a Chief Commercial Officer
13 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA to start trading today on the SIX Swiss Exchange
06 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
20 Jun 2018 7:49 am GNW     ObsEva SA ObsEva Announces Pricing of Follow-on Public Offering
18 Jun 2018 9:31 pm GNW     ObsEva SA ObsEva Announces Launch of Proposed Follow-on Public Offering
  12:00 pm GNW     ObsEva SA ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
15 Jun 2018 9:00 pm GNW     ObsEva SA ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
01 Jun 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Seek SIX Share Listing
31 May 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
16 May 2018 12:00 pm GNW     ObsEva SA ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
08 May 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
23 Apr 2018 12:00 pm GNW     ObsEva SA ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
16 Apr 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
26 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018
09 Mar 2018 1:47 pm GNW     ObsEva SA ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
  12:00 pm GNW     ObsEva SA ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
02 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
01 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
26 Feb 2018 12:00 pm GNW     ObsEva SA ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
23 Feb 2018 9:00 pm GNW     ObsEva SA ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
07 Feb 2018 12:00 pm GNW     ObsEva SA ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
01 Feb 2018 12:00 pm GNW     ObsEva SA Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
05 Jan 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t